Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 164   

Articles published

NVS 80.02 -0.29 (-0.36%)
price chart
Novartis AG (ADR) (NYSE:NVS) Sells 14 Drug Brands Worth $293 Million To Sun In ...
Novartis AG (ADR) (NYSE:NVS) has sold more than a dozen drugs to India's Sun Pharmaceutical in Japan. The development follows a trend that has become popular among major pharmaceutical companies.
Can Novartis AG (ADR) Reach Financial Stability via Restructuring?
As Novartis AG (ADR) (NYSE:NVS) head of pharmaceuticals, David Epstein, announced his departure from the company, it initiated the process of restructuring the business portfolios.
Will Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) And Novartis AG (ADR ...
It is not clear whether Teva's Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Novartis AG (ADR)(NYSE:NVS) are trying to fend off copy cats.
Novartis AG (ADR) (NYSE:NVS) Stops Phase III Trial of Arzerra for Pemphigus ...
Seven months after acquiring the autoimmune indications rights to Arzerra from GlaxoSmithKline plc (ADR) (NYSE:GSK), Novartis AG (ADR) (NYSE:NVS) has ended the Phase III trial of Genmab A/S' (CPH:GEN) drug on those suffering from pemphigus ...
Pfizer Inc, Sanofi SA (ADR), Novartis AG (ADR): Who Will Acquire Medivation Inc?
As the merger and acquisition (M&A) spree is booming, multiple pharmaceutical companies have put Medivation Inc. (NASDAQ:MDVN) on the top of their acquisition list.
How Many Novartis AG (ADR) (NYSE:NVS)'s Analysts Are Bearish?
Out of 8 analysts covering Novartis Ag (NYSE:NVS), 1 rate it a “Buy”, 2 “Sell”, while 5 “Hold”. This means 13% are positive.
Bryn Mawr Trust Company Decreased Stake in Novartis Ag Sponsored Adr (NYSE ...  Consumer Eagle
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Novartis AG (ADR) Aiming to Target Biosimilar Market by 2020
By 2020, Novartis AG (NYSE:NVS) plans to launch a number of biosimilar versions of the blockbuster drugs in order to enter multiple therapeutic markets.
Amgen, Inc. (NASDAQ:AMGN) Has Sued Novartis' AG (ADR) (NYSE:NVS) Sandoz Unit ...
Top-selling anti-inflammatory drug Enbrel from Amgen, Inc. (NASDAQ:AMGN) is facing steep competition from biosimilars that are hitting the market at a very rapid speed.
Amgen Inc to Face Off Pfizer & Novartis to Save Key Drugs  Bidness ETC
Citi Downgrades Novartis Following SAG Investigation
Citi has downgraded Novartis AG (ADR) (NYSE: NVS) to Neutral from Buy on SAG investigation. Analyst Andrew Baum reported, "The ongoing action of the formidable State Attorney General (SAG) of the Southern District of NY, Preet Bharara, casts a ...
Novartis AG (ADR) (NVS) Under Investigation for 'Sham' Events